Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia.
Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, Schroeder T, Fransecky L, Steffen B, Krause SW, Scholl S, Hochhaus A, Sauer T, Kraus S, Schäfer-Eckart K, Kaufmann M, Jost E, Brümmendorf TH, Schliemann C, Mikesch JH, Krug U, Hänel M, Morgner A, Schaich M, Neubauer A, Repp R, Niemann D, Seggewiss-Bernhardt R, Meinhardt A, Kullmer J, Kaiser U, Blau W, Kiani A, Grigoleit GU, Giagounidis A, Wurm AA, Altmann H, Middeke JMM, Schetelig J, Müller-Tidow C, Stölzel F, Baldus CD, Platzbecker U, Serve H, Bornhäuser M, Thiede C, Röllig C. Ruhnke L, et al. Among authors: fransecky l. Blood Adv. 2024 Nov 6:bloodadvances.2024013304. doi: 10.1182/bloodadvances.2024013304. Online ahead of print. Blood Adv. 2024. PMID: 39504561
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, Noppeney R, Hanoun M, Kaufmann M, Weinbergerova B, Schäfer-Eckart K, Sauer T, Neubauer A, Burchert A, Baldus CD, Mertová J, Jost E, Niemann D, Novák J, Krause SW, Scholl S, Hochhaus A, Held G, Szotkowski T, Rank A, Schmid C, Fransecky L, Kayser S, Schaich M, Kramer M, Fiebig F, Haake A, Schetelig J, Middeke JM, Stölzel F, Platzbecker U, Thiede C, Müller-Tidow C, Berdel WE, Ehninger G, Mayer J, Serve H, Bornhäuser M. Röllig C, et al. Among authors: fransecky l. J Clin Oncol. 2025 Jan;43(1):65-74. doi: 10.1200/JCO.24.00235. Epub 2024 Sep 16. J Clin Oncol. 2025. PMID: 39284116 Clinical Trial.
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
Schroeder T, Martens T, Fransecky L, Valerius T, Schub N, Pott C, Baldus C, Stölzel F. Schroeder T, et al. Among authors: fransecky l. Intensive Care Med. 2024 Sep;50(9):1459-1469. doi: 10.1007/s00134-024-07576-4. Epub 2024 Aug 22. Intensive Care Med. 2024. PMID: 39172238 Free PMC article. Review.
Proteomic profiling reveals ACSS2 facilitating metabolic support in acute myeloid leukemia.
Mochmann LH, Treue D, Bockmayr M, Silva P, Zasada C, Mastrobuoni G, Bayram S, Forbes M, Jurmeister P, Liebig S, Blau O, Schleich K, Splettstoesser B, Nordmann TM, von der Heide EK, Isaakidis K, Schulze V, Busch C, Siddiq H, Schlee C, Hester S, Fransecky L, Neumann M, Kempa S, Klauschen F, Baldus CD. Mochmann LH, et al. Among authors: fransecky l. Cancer Gene Ther. 2024 Sep;31(9):1344-1356. doi: 10.1038/s41417-024-00785-5. Epub 2024 Jun 8. Cancer Gene Ther. 2024. PMID: 38851813 Free PMC article.
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
Neumann M, Beder T, Bastian L, Hänzelmann S, Bultmann M, Wolgast N, Hartmann A, Trautmann H, Ortiz-Tanchez J, Schlee C, Schroeder M, Fransecky L, Vosberg S, Fiedler W, Alakel N, Heberling L, Kondakci M, Starck M, Schwartz S, Raffel S, Müller-Tidow C, Schneller F, Reichle A, Burmeister T, Greif PA, Brüggemann M, Gökbuget N, Baldus CD. Neumann M, et al. Among authors: fransecky l. Leukemia. 2024 Jun;38(6):1213-1222. doi: 10.1038/s41375-024-02264-0. Epub 2024 May 14. Leukemia. 2024. PMID: 38744920 Free PMC article.
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Ravandi F, Subklewe M, Walter RB, Vachhani P, Ossenkoppele G, Buecklein V, Döhner H, Jongen-Lavrencic M, Baldus CD, Fransecky L, Pardee TS, Kantarjian H, Yen PK, Mukundan L, Panwar B, Yago MR, Agarwal S, Khaldoyanidi SK, Stein A. Ravandi F, et al. Among authors: fransecky l. Leuk Lymphoma. 2024 Sep;65(9):1281-1291. doi: 10.1080/10428194.2024.2346755. Epub 2024 May 7. Leuk Lymphoma. 2024. PMID: 38712673 Clinical Trial.
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, Schliemann C, Mikesch JH, Steffen B, Sauer T, Hanoun M, Schafer-Eckart K, Krause SW, Hanel M, Einsele H, Jost E, Brummendorf TH, Scholl S, Hochhaus A, Neubauer A, Burchert A, Kaufmann M, Niemann D, Schaich M, Blau W, Kiani A, Gorner M, Kaiser U, Kullmer J, Weber T, Berdel WE, Ehninger G, Muller-Tidow C, Platzbecker U, Serve H, Bornhauser M, Rollig C, Baldus CD, Fransecky L. Baden D, et al. Among authors: fransecky l. Haematologica. 2024 Aug 1;109(8):2469-2477. doi: 10.3324/haematol.2024.285225. Haematologica. 2024. PMID: 38654660 Free PMC article.
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, Noppeney R, Schäfer-Eckart K, Wendelin K, Mikesch JH, Middeke JM, Reimann M, Fiebig F, Zukunft S, Wermke M, Serve H, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M. Röllig C, et al. Among authors: fransecky l. Br J Haematol. 2024 Jun;204(6):2254-2258. doi: 10.1111/bjh.19436. Epub 2024 Apr 9. Br J Haematol. 2024. PMID: 38593353 Clinical Trial.
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.
Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Hiddemann W, Görlich D, Sauerland C, Steffen B, Einsele H, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Ruhnke L, Schetelig J, Middeke JM, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Bornhäuser M, Herold T, Thiede C, Röllig C. Eckardt JN, et al. Among authors: fransecky l. Leukemia. 2023 Nov;37(11):2282-2285. doi: 10.1038/s41375-023-02016-6. Epub 2023 Sep 7. Leukemia. 2023. PMID: 37679502 Free PMC article. No abstract available.
29 results